{"entity":{"id":"da-prasinezumab","kind":"drug","name":"Prasinezumab","aka":[],"tldr":"Prasinezumab is an investigational synuclein antibody studied mainly in Parkinson’s disease. It is not an approved dementia medicine.","summary":"Listed as a same-target neighbour for Lewy-body biology. Parkinson’s trial results do not equal a dementia indication. Trial-only access.","status":"phase-2","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT03100149","url":"https://clinicaltrials.gov/study/NCT03100149"}],"tags":["dementia-atlas"],"related":[],"cancers":["parkinsons-disease-dementia","dementia-with-lewy-bodies"],"sections":[],"technologies":[],"targets":["da-target-alpha-synuclein"],"drugs":[],"companies":["da-roche"],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-prasinezumab"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"mAb","mechanism":"Investigational antibody against aggregated alpha-synuclein (primarily Parkinson’s programmes).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/da-prasinezumab/","neighbours":{"cancer":[{"id":"dementia-with-lewy-bodies","kind":"cancer","name":"Dementia with Lewy bodies","route":"/diagnoses/dementia-with-lewy-bodies/"},{"id":"parkinsons-disease-dementia","kind":"cancer","name":"Parkinson’s disease dementia","route":"/diagnoses/parkinsons-disease-dementia/"}],"target":[{"id":"da-target-alpha-synuclein","kind":"target","name":"Alpha-synuclein","route":"/targets/da-target-alpha-synuclein/"}],"company":[{"id":"da-roche","kind":"company","name":"Roche","route":"/companies/da-roche/"}],"trial":[{"id":"da-trial-prasinezumab","kind":"trial","name":"Prasinezumab (PASADENA / related)","route":"/trials/da-trial-prasinezumab/"}]}}